ArticleFrontiers in cardiovascular medicine2022

Physical performance and glycemic control under SGLT-2-inhibitors in patients with type 2 diabetes and established atherosclerotic cardiovascular diseases or high cardiovascular risk (PUSH): Design of a 4-week prospective observational study.

Devine S Frundi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.